ArticleNature communications2024
Cefazolin shifts the kidney microbiota to promote a lithogenic environment.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The gut-kidney microbiome-oxalate axis in calcium oxalate nephrolithiasis: mechanisms and microbiome-based interventions.Frontiers in cellular and infection microbiology · 2026Pooled it
- Novel insights into the role of the renal interstitial microenvironment in Randall's plaque formation (Review).International journal of molecular medicine · 2026Review
- Lactobacillus acidophilus abolishes oxalate-mediated renal epithelial barrier disruption and calcium oxalate monohydrate crystal adhesion to renal epithelial cells.Cellular & molecular biology letters · 2026Article
- Linkage of gut microbiota dysbiosis to chronic kidney disease in patients with graded proteinuria levels.Microbiology spectrum · 2026Article
- Predicting probiotic success: lessons from Oxalobacter and oxalate metabolism.NPJ biofilms and microbiomes · 2026Review
- The Application of Nanomaterials in Kidney Stone Disease: Emerging Strategies for Early Diagnosis, Targeted Therapy, and Prevention.International journal of nanomedicine · 2026Review
- Multi-habitat microbiome profiling identifies habitat-dependent alterations and complementary discriminatory information in urolithiasis.Frontiers in cellular and infection microbiology · 2026Article
- Renal tissue microbiota and metabolite profiling reveal dysregulated signatures in diabetic kidney disease.Frontiers in microbiology · 2026Article
- A real-world pharmacovigilance study of FDA adverse event reporting system events for cefazolin.Medicine · 2025Observational
- Microbiota and kidney disease: the road ahead.Nature reviews. Nephrology · 2025Review
- Impact of study design, contamination, and data characteristics on results and interpretation of microbiome studies.mSystems · 2025Article
- Investigation of the predictive value of Hounsfield units in predicting stone culture results in urinary stone disease.Scientific reports · 2025Article
- The kidney harbours a microbiota that may influence lithogenesis.Nature reviews. Nephrology · 2025Article
- Mechanism of Nephrolithiasis: Does the Microbiome Play a Role?European urology focus · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Clinical studies of the urinary tract microbiome, termed urobiome, suggest a direct, antibiotic-dependent, impact of the urobiome on kidney physiology. However, evidence for kidney bacteria comes from indirect sources or infected tissue. Further, it is unclear how antibiotics impact kidney bacteria. Here we show direct evidence for the presence of bacteria in the kidneys, with microniches in nephrons. In murine kidneys, administration of cefazolin, a commonly used perioperative antibiotic, led to a loss of uroprotective Lactobacillus spp. and proliferation of Enterobacteriaceae (which includes many known uropathogens). This effect was dependent on treatment duration, with recovery post treatment. Uroprotective L. crispatus and a strain of stone-associated E. coli differentially influenced calcium oxalate (CaOx) crystallization through the incorporation of CaOx inhibitors or promoters, respectively. In humans, microbial signatures were identified in the kidney, with unique niches between the glomeruli and tubules, established through RNA sequencing analysis and direct imaging of two independent populations. Collectively, findings support the hypothesis that the kidneys harbor a stable and antibiotic-responsive microbiota that can influence CaOx lithogenesis. The presence of unique, age-dependent microbial signatures in the glomeruli and tubuli carry implications for non-infectious kidney diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.